QA GLP audits. Alain Piton. Antipolis,, France. alain.piton@galderma.com



Similar documents
QUALITY RISK MANAGEMENT (QRM): A REVIEW

Best Practice In A Change Management System

Quality Risk Management Tools Quality Risk Management Tool Selection When to Select FMEA: QRM Tool Selection Matrix

Risk Assessment for Medical Devices. Linda Braddon, Ph.D. Bring your medical device to market faster 1

Improved Utilization of Self-Inspection Programs within the GMP Environment A Quality Risk Management Approach

Quality Risk Management

Application of Quality Risk Management to Pharmaceutical Operations. Eldon Henson, Vice President, Quality Operations

FMEA and FTA Analysis

Guidance for Industry

Quality Risk Management The Pharmaceutical Experience Ann O Mahony Quality Assurance Specialist Pfizer Biotech Grange Castle

QUALITY RISK MANAGEMENT

3.0 Risk Assessment and Analysis Techniques and Tools

Quality Risk Management in Pharmaceutical Industry: A Review

Empowering the Quality and Regulatory Compliance Functions

Guidance for Industry: Quality Risk Management

Quality Risk Management ICH Q9 & ISO Presented by Michael Kerr 11 th November 2011

Impact Assessment in a Science & Risk Based Environment. R. Legland 11/04/11

Risk-Based Environmental Monitoring. Marsha Stabler Hardiman Senior Consultant Concordia ValSource Wednesday September 17, 2014 FDA/PQRI

Risk Assessment Tools for Identifying Hazards and Evaluating Risks Associated with IVD Assays

Effective Root Cause Analysis For Corrective and Preventive Action

Quality Risk Management Principles and Industry Case Studies

Auditing HACCP Programs

Controlling Risks Risk Assessment

Risk Assessment and Management. Allen L. Burgenson Manager, Regulatory Affairs Lonza Walkersville Inc.

Quality Risk Management Understanding and Control the Risk in Pharmaceutical Manufacturing Industry

Title:: Effective GMP AUDITS for APIs and Formulation Pharma Companies By G.Sundar-Director/Consultant PharmQA Compliance solutions

ORACLE CONSULTING GROUP

Edwin Lindsay Principal Consultant. Compliance Solutions (Life Sciences) Ltd, Tel: + 44 (0) elindsay@blueyonder.co.

GLP vs GMP vs GCP Dominique Pifat, Ph.D., MBA The Biologics Consulting Group

Comparison Chart of FDA and EPA Good Laboratory Practice (GLP) Regulations and the OECD Principles of GLP

Quality Risk Analysis: Value for Money in the Pharmaceutical Industry

Design Verification The Case for Verification, Not Validation

4. Critical success factors/objectives of the activity/proposal/project being risk assessed

Corrective and Preventive Action Background & Examples Presented by:

FAILURE INVESTIGATION AND ROOT CAUSE ANALYSIS

ICH Q9 Quality Risk Management - an industry view. Peter H. Gough, Eli Lilly and Company

The use of risk assessment tools for microbiological assessment of cleanroom environments. by Tim Sandle

Guidance for Industry. Q10 Pharmaceutical Quality System

With the introduction of GAMP 5, A

New Guidelines on Good Distribution Practice of Medicinal Products for Human Use (2013/C 68/01)

Commercial Manufacturing - Qualification & Validation-related GMP Deficiencies and Other Lifecycle Considerations

Risk-Based Validation of Commercial Off-the-Shelf Computer Systems

Session 6: WHO Prequalification Programme. Key Process Steps WHO: Medicines UNFPA: Condoms and IUDs

Overview of Medical Device Design Controls in the US. By Nandini Murthy, MS, RAC

RISK MANAGEMENT FOR INFRASTRUCTURE

QUALITY CONTROL AND QUALITY ASSURANCE IN CLINICAL RESEARCH

Hazard Analysis and Critical Control Points (HACCP) 1 Overview

Validation Consultant

Media fills Periodic performance qualification (Re-Validation)

Human Research Protection Program Good Clinical Practice Guidance for Investigators Investigator & Research Staff Responsibilities

ASSESSMENT OF QUALITY RISK MANAGEMENT IMPLEMENTATION

Life Sciences Product Development Artifacts Survey Results

How to implement a Quality Management System

Reflection paper for laboratories that perform the analysis or evaluation of clinical trial samples

Quality Assurance. Disclosure for Lilli Møller Andersen. No relevant financial relationships exist for any issue mentioned in this presentation

Standard Operating Procedure Title: Quality Risk Management Techniques

PHARMACEUTICAL QUALITY SYSTEM Q10

Annex 2. WHO guidelines on quality risk management. 1. Introduction Glossary Quality risk management process 70

Establishment of a Quality Systems approach to Clinical Site Management An Overview of Standard Operating Procedures (SOPs)

Risk Management Primer

OECD and US GLP Applications. Del W. Huntsinger. BASF, Reserach Triangle Park, USA

Part 1 Overview of clinical governance Clinical governance the concept 1-3

Considerations When Validating Your Analyst Software Per GAMP 5

Reliability Analysis A Tool Set for. Aron Brall

Managing Clinical Trial Risk: It's a Tough Job, But One Person Has To Do It

Deviation Handling and Quality Risk Management

A Risk Management Standard

Ann Ist Super Sanità 2008 Vol. 44, No. 4:

Regulatory Submission: Applying GLP in Surgical Efficacy Studies

International GMP Requirements for Quality Control Laboratories and Recomendations for Implementation

Marie-Claire Rickard, GCP & Governance Manager Rachel Fay, GCP & Governance Manager Elizabeth Clough, R&D Operations Manager

What is necessary to provide good clinical data for a clinical trial?

Approaching the Response to Audit Observations

FINAL DOCUMENT. Global Harmonization Task Force

Resources Based, Manufacturing and Consumer Goods Industries Chemicals Industry

FAMI-QS Certification Rules for Operators. Rules for Operators

Hazard Identification and Risk Assessment for the Use of Booster Fans in Underground Coal Mines

U.S. Food and Drug Administration

World Health Organization Prequalification of Medicines

FOOD FOR THOUGHT Topical Insights from our Subject Matter Experts

AUDITOR GUIDELINES. Responsibilities Supporting Inputs. Receive AAA, Sign and return to IMS with audit report. Document Review required?

EffiValidation 3.0 software basic training module

Failure Modes and Effects Analysis (FMEA)

Risk management for external beam radiotherapy Recommendations (draft)

The Medical Device Industry in Korea: Strategies for Market Entry

Combination Products. Presented by: Karen S. Ginsbury For: IFF March PCI Pharma

Core Training Outline

ICH guideline Q10 on pharmaceutical quality system

Analyzing Risks in Healthcare. February 12, 2014

White paper: How to implement a Quality Management System

Design, conduct experiments, analyze, data, implementation strategies, recommendations findings communicated; (labs)

University of Paderborn Software Engineering Group II-25. Dr. Holger Giese. University of Paderborn Software Engineering Group. External facilities

Edwin Lindsay Principal Consultant. Compliance Solutions (Life Sciences) Ltd, Tel: + 44 (0) elindsay@blueyonder.co.

MINISTRY OF HIGHER EDUCATION UNIVERSITY OF HAIL COLLEGE OF PHARMACY

Regulatory Expectations for GMP: What s Happening. Patricia Weideman, PhD Director, Product Quality & Occupational Toxicology Genentech, Inc.

A Roadmap for Competency Assessment ASCLS-NJ Spring Seminar April 24, 2014

Risk assessment is used as a

PROCEDURES FOR HANDLING OOS RESULTS

The Global Guideline for GCP Audit

1

Transcription:

Risk based assessment applied to QA GLP audits Alain Piton Galderma R&D, Sophia-Antipolis Antipolis,, France alain.piton@galderma.com

RISK BASED ASSESSMENT FOR GLP AUDITS INTRODUCTION Since the origin of GLP the standard plan for QA inspections is based upon the concept of study and critical phases. The concept of facility-based and process-based inspections emerges since a decade. The default standard in the industry is still driven by the studies and the idea that facility-based and process-based should be performed quarterly. The concept of processes, brought by the ISO standards, and the business need of optimizing the use of resources lead us toward a process based inspection concept, driven by the risks associated to the processes This presentation is aimed to suggest to what extent this approach is GLP compatible

GLP inspections Authorities requirements FDA: Inspect each non clinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection showing the date of the inspection, the study inspected, the phase or segment of the study inspected, the person performing the inspection, findings and problems, action recommended and taken to resolve existing problems, and any scheduled date for reinspection. Any problems found during the course of an inspection which are likely to affect study integrity shall be brought the attention of the study director and management immediately. OECD:conduct inspections to determine if all studies are conducted in compliance with these Principles of Good Laboratory Practice. Inspections should also determine that study plans and Standard Operating Procedures have been made available to study personnel and are being followed. Inspections can be of three types as specified by Quality Assurance Program Standard Operating Procedures: Study-based inspections, Facility-based inspections, Process-based inspections. Japan: The quality assurance manager should implement by oneself, or designate a person in charge of study to implement the following: (3) confirm that inspections are conducted periodically at intervals appropriate to assure the reliability of study in compliance with this ordinance; prepare records specifying the nature of inspection, inspection results, actions taken to solve problems, and the date when reinspection is scheduled etc., then store them with signature or sign and seal; Ministry of Health and Welfare Ordinance No.21, 1997

RISK BASED ASSESSMENT FOR GLP INSPECTIONS CURRENT SITUATION IN THE GLP WORLD Still a lot of critical phases approach Process and facility based inspections design unclear Periodicity defined (often quarterly) processes are frequently periodic inspections of phases Frequent expectations by the authorities outside EU to maintain the status-quo

RISK BASED ASSESSMENT FOR GLP INSPECTIONS Critical phases approach: Consequences Studies are comparable to products, QA inspections could be looked at as a QC of the product Many phases are audited again and again with very little to no added value Many interfaces between phases are rarely or never evaluated Information obtained is hardly useful for a CAPA or a continuous improvement process BUT Studies are clean (product may be released) Compliance is granted

RISK BASED ASSESSMENT FOR GLP INSPECTIONS What the processes risk based assessment can provide? A vision of the activity through processes regardless of the product (in this case the study) An inspection strategy based on actual risks An optimized and thorough use of QA resources The assurance of overseeing all activities and interfaces Information for continuous improvement

How to define processes Main challenge: find the right granularity of process mapping and design Looking inside the processes: Drives the content of the process inspection Approach used for Quality risk assessment, process improvement and risk elimination and control The areas of risk are identified and analyzed The risk is controlled Looking the processes as components of the system: approach used for the purpose of the inspections planning The risk is assessed and monitored The 2 levels are complementary and sequential

Categories of processes Categories Production Processes Support processes Management processes Example toxicology study In vivo phase (dosing, clinical obs and exams, necropsy) Test item (synthesis, handling, formulation, analysis) Ex vivo phase (clinpath, anapath) Data management, statistics and reports) Animal husbandry Facilities management Metrology, IM SOPs Training and competencies

What is a risk? RISK: What are we talking about Intuitively understand Risk as something harmful. In the GLP world it will be an undesirable event that put a study, a project or a facility in jeopardy Three key components of Risk: Probability that event will occur Severity of the event Detectability of the event To effectively assess risk, all components must be evaluated

Which risks are in the scope of GLP inspections Outside the scope Risk of creating a harmful situation at the user level Inappropriate safety assessment leading to false scientific conclusion Inappropriate scientific study design Workers safety (safety measures or inaccurate safety data) Risk of inefficacy (inappropriate testing / misinterpretations) These risks are not addressed in this presentation

In Scope Which risks are in the scope of GLP inspections Risk of GLP non compliance (GLP principles, protocols or SOPs breaching or violation) with financial, regulatory or legal consequences Business risk (need for repeated studies, delays in registration / submission) Business risk (sites disqualification, image) Risk of creating a harmful situation for people or environment Fraudulent activities that hide some characteristic of the test substance Study misconduct that leads to wrong data thus bad conclusion These risks are the ones addressed in this presentation

How to assess risk The methods Have very well defined processes that will be subjected to assessment and inspection (comparability) Big variety of tools available for risk assessment Basic Tools: the 5 steps approach, Preliminary Hazard Analysis, PHA Matrix and Risk Table More sophisticated: FMEA, FMECA, HACCP, FTA Select one; keep it for time (to ensure comparability of assessments with time) Obtain a figure that will allow discrimination and prioritization Reassess the risk after every process inspection (assessment update)

How to assess risk WHO does what? PARTNERSHIP! Process mapping and processes design QA (has the tool box) Personnel (has the knowledge) Risk Assessment QA (has the knowledge) Personnel (validate the assessment) Risk based inspection plan QA (knows the job) Management (approve the plan) The result belongs to the organization

How to assess risk Given the GLP nature of the risk, necessary information for a process risk assessment includes (but not limited to) Each topic may be associated with a number from a numeric scale Total of numbers contributes to overall assessment Characteristic of the process Novelty operators awareness / competency History of the process (last 12 months) QA findings (number and grading) Regulatory situation of the process Regulatory inspection history (last inspection) Process is on the authorities radar screen Process scope The process is a component of submitted studies The process supports regulated / submitted studies The process supports site Compliance The process is outside the scope of compliance The process contains Animal Welfare component Criticality of the process Failure of the process may negatively affect quality and / integrity of data Failure of the process may invalidate studies Failure of the process may impact site compliance

How to plan the process inspections Define frequencies and justify Minimal (e.g. once a year) Maximal (e.g. if a process needs to be inspected more than once a month, consider inspecting every activity of the process according to study specific critical phases plan) Prioritize according to risk level Adjust to available resources Revisit risk assessment and inspection plan after all inspections

Is RISK approach GLP compliant potential caveats from a regulatory standpoint. Compatibility of risk approach with the GLP regulatory requirements Not all studies will be inspected To an extent, critical phases / study specific inspections could never happen (with the exception of protocols and reports) How to demonstrate the GLP goals are fulfilled although the some of the GLP specific requirements may not be. Provide the organization and the monitoring authorities with the assurance that all studies will meet the requirement Means provide the assurance that the process will deliver what it was designed for.

Risk based inspection plan advantages: Formalizing QA decision making Documentation Data driven Improved process understanding Confronting key Quality questions What is acceptable What is most important What is most value added Consistency/ease of decision making when event occurs

RISK BASED ASSESSMENT FOR GLP AUDITS CONCLUSION This is my statement, please feel free to disagree Inspecting processes based on a risk assessment provides valuable information while making the best use of QA common sense, knowledge, talents and resources Such a plan, with the addition of each protocol being audited and each report being reviewed fulfills regulatory requirements

And finally, QA continuously improves its practices QA QA

BACK-UP SLIDES

How does risk management compare to root cause analysis Risk Management looks at a dataset, and what are the potential future consequences: Identifies potential risks Analyzes potential risks Evaluates potential risks Controls potential risks Actions are all focused on making decisions related to potential future events RCA is Retrospective, examining what has already occurred to: Determine WHAT happened Determine WHY it happened Determine HOW it can be prevented from happening again

Selecting a Risk Assessment Method when the risk factors are more qualitative than quantitative. Risk Ranking and Filtering (RRF), or Preliminary Hazards Analysis (PHA). When there is also an element of detectability chose to use Failure Mode and Effects Analysis (FMEA).

Simple Tools Charting Brainstorming Statistical Tools Risk Ranking/Filtering Preliminary Hazards Analysis Moderate QRM Tools FMEA/FMECA, HACCP Variation Risk Management Detailed QRM Tools Probabilistic Risk Analysis, Decision Trees, Event Tree Analysis, Fault Tree Analysis